New York: Regulus (NASDAQ:RGLS) Stock Has Just Had Its Buy Rating Reiterated by Wedbush. Shares now Have a $3.0000 Target

May 18, 2018 - By Tina Thibodeau

Regulus Therapeutics Inc. (NASDAQ:RGLS) Logo

Investors sentiment decreased to 1.16 in 2017 Q4. Its down 0.19, from 1.35 in 2017Q3. It is negative, as 7 investors sold Regulus Therapeutics Inc. shares while 12 reduced holdings. 10 funds opened positions while 12 raised stakes. 53.17 million shares or 9.64% less from 58.85 million shares in 2017Q3 were reported.

Manufacturers Life Insurance The, a Ontario – Canada-based fund reported 6,057 shares. 45,800 were reported by Quantitative Inv Management Ltd Liability. Morgan Stanley holds 0% of its portfolio in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 2,872 shares. Susquehanna International Group Inc Ltd Liability Partnership accumulated 32,631 shares or 0% of the stock. Rhenman Ptnrs Asset Management Ab stated it has 492,878 shares or 0.07% of all its holdings. Guggenheim Ltd Limited Liability Company accumulated 25,867 shares. Broadfin Limited Liability Company holds 0.26% or 1.51 million shares. Mariner Wealth Advsrs Lc holds 0% or 37,400 shares. Washington Tru Bancshares owns 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 155 shares. Fmr Lc reported 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). Bnp Paribas Arbitrage Sa has 4 shares for 0% of their portfolio. Dowling Yahnke Limited Liability Corporation stated it has 11,500 shares. Vanguard Grp reported 2.46 million shares. Nea Management Ltd Llc invested in 10.99 million shares. The Connecticut-based Bourgeon Cap Management Llc has invested 0.04% in Regulus Therapeutics Inc. (NASDAQ:RGLS).

Regulus (NASDAQ:RGLS) Rating Reaffirmed

Recently, In analysts note sent to investors on 17 May, Regulus (NASDAQ:RGLS) shares have had their Buy Rating reaffirmed by stock research analysts at Wedbush, who currently has a $3.0000 price target on firm. This target by Wedbush would suggest the possibile upside of 322.54 % from the previous stock close.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Among 5 analysts covering Regulus (NASDAQ:RGLS), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Regulus has $4.0 highest and $1 lowest target. $1.67’s average target is 135.21% above currents $0.71 stock price. Regulus had 8 analyst reports since December 11, 2017 according to SRatingsIntel. Wedbush maintained it with “Buy” rating and $4.0 target in Monday, December 11 report. The stock has “Market Perform” rating by BMO Capital Markets on Thursday, March 8. The firm has “Buy” rating given on Wednesday, December 20 by Wedbush. The rating was maintained by Wedbush on Monday, March 12 with “Buy”. FBR Capital initiated Regulus Therapeutics Inc. (NASDAQ:RGLS) rating on Tuesday, March 27. FBR Capital has “Hold” rating and $100 target. Wedbush maintained the stock with “Buy” rating in Thursday, February 8 report.

The stock 0.07% or $0 during the last trading session, reaching $0.71. It is down 52.76% since May 18, 2017 and is downtrending. It has underperformed by 64.31% the S&P500.

Analysts await Regulus Therapeutics Inc. (NASDAQ:RGLS) to report earnings on August, 7. They expect $-0.17 EPS, up 58.54 % or $0.24 from last year’s $-0.41 per share. After $-0.15 actual EPS reported by Regulus Therapeutics Inc. for the previous quarter, Wall Street now forecasts 13.33 % negative EPS growth.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company has market cap of $74.07 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. It currently has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

More news for Regulus Therapeutics Inc. (NASDAQ:RGLS) were recently published by:, which released: “Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global …” on May 17, 2018.‘s article titled: “Regulus Therapeutics’ (RGLS) CEO Joseph Hagan on Q1 2018 Results – Earnings Call Transcript” and published on May 11, 2018 is yet another important article.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: